Corcept Therapeutics Inc (CORT) valuation history
$85.86
Latest weekly close · Market cap $10.2B
Share CORT EV/EBITDA history
As of
CORT's EV/EBITDA is unavailable because recent financial data is missing.
No EV/EBITDA chart for CORT right now
CORT has no current EV/EBITDA reading to compare with its history.
See CORT's P/E historyEV/EBITDA
n/anot ranked
No EV/EBITDA rank: recent financial data is missing.
Growth, last 12 months vs the year before
- Revenue
- +16%accelerating
- EPS
- -63%
Price vs revenue and EPS, indexed to 100
Each line starts at 100 at its first positive reading over the last five years. Revenue and EPS change at fiscal quarter ends.
PriceRevenue, last 12 monthsEPS, last 12 months100 = first reading
EV/EBITDA at each year-end
The last weekly reading of each year, and its percentile against the five years before it.
| Year-end | EV/EBITDA | 5-year percentile |
|---|---|---|
| 62.1× | 81 | |
| n/a | Too little history | |
| 32.9× | 99 | |
| n/a | Too little history | |
| 17.8× | 40 | |
| 21.2× | 51 | |
| 12.2× | 1 | |
| 17.9× | 7 | |
| 60.6× | 9 | |
| 117.9× | Too little history |
Loading peers and related research…
About this history
- What is CORT's current EV/EBITDA?
- CORT's EV/EBITDA is unavailable because recent financial data is missing.
- What is CORT's five-year median EV/EBITDA?
- 26.6x. Half of CORT's weekly readings over the last five years were higher and half were lower. This page has 534 weekly readings, from Aug 1, 2016 to Oct 19, 2026.
- Does a low historical rank mean a stock is a buy?
- No. The rank compares CORT only with its own past. Slower growth or more risk can justify a lower multiple than before. P/E uses earnings and P/S uses revenue from the last twelve months.